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In the wake of the Poly Implant Prosthèse breast implant 
and the metal-on-metal incidents, the inherent flaws of 
European regulatory systems for medical products and 
devices have been highlighted once again.1 In lieu of the 
approximately 70 notifying bodies largely setting their 
own regulatory standards in the European Union,1 the US 
has one central regulatory authority to approve medical 
products and devices.2 According to Samuel et al, between 
1982 and 2014, 70 original orthopaedic devices were 
approved through the US Food and Drug Administration’s 
(FDA) premarket approval pathway (PMA).3 The PMA, 
which requires clinical data, is the most rigorous pathway 
that high-risk medical devices can undergo prior to being 
introduced on the market. Despite this, of these 70 
devices, 12 were subsequently subjected to FDA recalls 
during their lifespans, and no less than 765 post-market 
modifications were recorded.3 Twenty-two percent of 
these post-market modifications either significantly altered 
components or the device design. Class III devices (which 
include metal-on-metal hip implants) were intended to 
undergo PMA. However, because of a legislative loophole, 
metal-on-metal implants until recently usually only under-
went 501(k) clearance, meaning that they did not have to 
undergo studies showing safety or effectiveness.4
Partly caused by the challenges in the regulatory pro-
cesses, a substantial number of recalls and warnings are 
issued annually by medical companies, notifying bodies, 
governments and others. Although bad news allegedly trav-
els fast, it has been difficult to reach practicing surgeons or 
operating rooms with recall and safety information.5 Few sur-
geons have the time to actively stay on top of the many 
sources that provide information on recalls or field safety 
notices. To assist with this predicament, ArthroplastyWatch.
com (www.ArthroplastyWatch.com) was launched on 1 Feb-
ruary 2013 in Lund, Sweden. An independent (funded by a 
university grant) web service based on an electronic system 
which scans relevant sources of information on the Internet 
and disseminates safety information on implants, Arthroplas-
tyWatch.com is now celebrating its third birthday. Originally 
focussing on joint implants, the service has now been 
expanded to include devices in the orthopaedic field. Those 
interested in the service may subscribe free of charge and 
receive push email notifications when new information is 
published. Links to the original sources are always provided.
The underlying five-step process behind the service is out-
lined in Fig. 1. In short, a number of sources (e.g. health 
authorities, notifying bodies, national governments, medical 
companies, national quality registers, PubMed, professional 
societies) are continually searched for specific keywords 
through a computer system tailor-made for Arthroplasty-
Watch.com. Next, the information retrieved undergoes a 
two-step screening procedure to determine which informa-
tion is relevant and should be disseminated. The information 
is then drafted into a short alert and reviewed and cleared by 
at least one orthopaedic surgeon and a medical statistician 
for accuracy. After being given the go-ahead, the alert is 
posted on the webpage and subscribers will receive the 
information on their smartphones or computers.
To date, more than 100 alerts have been published, aver-
aging about one serious warning being published per week, 
and ArthroplastyWatch.com has had more than 16  500 
views since it was launched. An advisory board consisting of 
23 leading experts from 17 different nations is available.* 
The vast majority of the information that is released as alerts 
comes from the medical companies themselves, often in 
collaboration with government agencies or notifying bod-
ies. However, the information that is identified by the Arthro-
plastyWatch.com system primarily comes from government 
agencies in the US and Europe. In Table 1, the distribution of 
the different sources is outlined under the categories of lit-
erature (PubMed), medical company, government or noti-
fying body, national registries, or other.
The serious problem of spreading pertinent information 
to those involved with implants in order to remove faulty 
products from the market is still a reality. ArthroplastyWatch.
com is one tool that may help to facilitate the dissemination 
process. Equally important is the responsibility that each 
individual surgery unit has to act on a recall, as this might 
require increased patient surveillance. Sometimes only a 
specific batch or certain lot numbers are affected by a recall. 
To identify patients who should be informed and eventually 
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called back for additional examinations or even revision sur-
gery currently requires cumbersome, time-consuming and 
costly reviews of medical records. Furthermore, only some 
of the orthopaedic implant registers contain lot-specific 
information on the individual patient – yet this type of infor-
mation is highly valuable in assisting orthopaedic units in an 
expedient recall process, and it should be considered when 
building an implant registry.6
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Table 1. Original sources from which alerts originate (%)
Source/s** Literature (PubMed) Government or  
notifying body
Medical company National register Other
Number (%) 6 (5%) 86 (78%) 13 (12%) 2 (2%) 3 (3%)
**This table represents the sources from which ArthroplastyWatch.com received information. The data that caused the government/notifying body to issue an 
alert generally came from medical companies, registers or literature.
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Fig. 1 Five-step process used in ArthroplastyWatch.com.
